Autopsy and Case Reports
Autopsy and Case Reports
Clinical Case Report and Review

Clostridioides difficile infection leading to fulminant colitis with toxic megacolon

Fareed Rajack; Shawn Medford; Tammey Naab

Downloads: 2
Views: 380


Clostridioidesdifficile infection (CDI) is the culprit of millions of nosocomial infections in the United States. Programs that successfully decrease its incidence, therefore, render cost savings for the healthcare system. Toxic megacolon and perforation are two of the most significant complications with increased mortality rates. We report a 23-year-old nursing home resident hospitalized for fever, cough, and green sputum. After 3 days of antibiotic therapy, he developed abdominal distension, diarrhea, and vomiting and underwent a total colectomy. The colon was dilated to a maximum of 11 cm with markedly edematous mucosa and yellow pseudomembranes. Qualitative PCR of the stool detected Clostridioides difficile toxin B gene. While there is no consensus for the required interval between antibiotic treatment and CDI, this presentation 3 days after starting the antibiotic therapy is earlier than most proposed ranges.


Colectomy, Colitis, Colorectal Surgery, Diarrhea, Pseudomembranous


1 Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211-21. PMid:30945014.

2 Dutta SK, Girotra M, Kumar V, et al. Clinical predictors of fulminant colitis in patients with Clostridium difficile infection. Saudi J Gastroenterol. 2012;18(2):133-9. PMid:22421720.

3 Ramai D, Dang-Ho KP, Lewis C, et al. Clostridioides difficile infection in US hospitals: A National Inpatient Sample Study. Int J Colorectal Dis. 2020;35(10):1929-35. PMid:32556651.

4 Marra AR, Perencevich EN, Nelson RE, et al. Incidence and outcomes associated with Clostridium difficile Infections. JAMA Netw Open. 2020;3(1):e1917597. PMid:31913488.

5 Magill SS, O’Leary E, Janelle SJ, et al. Changes in prevalence of health care–associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732-44. PMid:30380384.

6 Sayedy L, Kothari D, Richards RJ. Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endosc. 2010;2(8):293-7. PMid:21160629.

7 Centers for Disease Control and Prevention (CDC). 2018 annual report for the emerging infections program for Clostridioides difficile infection [Internet]. Atlanta: CDC; 2022 [cited 2023 July 10]. Available from:

8 Khanna S, Gupta A. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;63:63.

9 Brown KA, Langford B, Schwartz KL, Diong C, Garber G, Daneman N. Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study. Clin Infect Dis. 2021;72(5):836-44. PMid:32069358.

10 Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42-8. PMid:21653301.

11 Eaton SR, Mazuski JE. Overview of severe Clostridium difficile infection. Crit Care Clin. 2013;29(4):827-39. PMid:24094379.

12 Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487-99. PMid:20424299.

13 Desai J, Elnaggar M, Hanfy AA, Doshi R. Toxic megacolon: background, pathophysiology, management challenges and solutions. Clin Exp Gastroenterol. 2020;13:203-10. PMid:32547151.

14 Jalan KN, Sircus W, Card WI, et al. An experience of ulcerative colitis. Gastroenterology. 1969;57(1):68-82. PMid:5305933.

15 Ciccocioppo R, Corazza GR. In-hospital mortality for toxic megacolon. Intern Emerg Med. 2018;13(6):837-8. PMid:30073474.

16 Tomita R, Munakata K, Tanjoh K. Role of non-adrenergic non-cholinergic inhibitory nerves in the colon of patients with ulcerative colitis. J Gastroenterol. 1998;33(1):48-52. PMid:9497221.

17 Tomita R, Tanjoh K. Role of nitric oxide in the colon of patients with ulcerative colitis. World J Surg. 1998;22(1):88-92, discussion 92. PMid:9465767.

18 Pons L, Droy-Lefaix M-T, Bueno L. Leukotriene D4 participates in colonic transit disturbances induced by intracolonic administration of Trinitrobenzene sulfonic acid in rats. Gastroenterology. 1992;102(1):149-56. PMid:1727747.

19 Snape WJ Jr, Kao HW. Role of inflammatory mediators in colonic smooth muscle function in ulcerative colitis. Dig Dis Sci. 1988;33(3, Suppl):65S-70S. PMid:2894283.

20 Doshi R, Desai J, Shah Y, Decter D, Doshi S. Incidence, features, in-hospital outcomes and predictors of in-hospital mortality associated with toxic megacolon hospitalizations in the United States. Intern Emerg Med. 2018;13(6):881-7. PMid:29948833.

21 Ausch C, Madoff RD, Gnant M, et al. Aetiology and surgical management of toxic megacolon. Colorectal Dis. 2006;8(3):195-201. PMid:16466559.

22 Greenstein AJ, Sachar DB, Gibas A, et al. Outcome of toxic dilatation in ulcerative and Crohn’s colitis. J Clin Gastroenterol. 1985;7(2):137-44. PMid:4008909.

23 Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis. Arch Surg. 2009;144(5):433-9, discussion 439-40. PMid:19451485.

24 Toshniwal R, Silva J Jr, Fekety R, Kim K-H. Studies on the epidemiology of colitis due to Clostridium difficile in hamsters. J Infect Dis. 1981;143(1):51-4. PMid:7217712.

25 Aberra FN. Clostridioides (Clostridium) difficile colitis [Internet]. Medscape; 2023 [cited 2023 July 10]. Available from:

26 Bartlett JG. Clostridium difficile infection. Infect Dis Clin North Am. 2017;31(3):489-95. PMid:28779831.

27 Panos MZ, Wood MJ, Asquith P. Toxic megacolon: the knee-elbow position relieves bowel distension. Gut. 1993;34(12):1726-7. PMid:8282262.

28 Danovitch SH. Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am. 1989;18(1):73-82. PMid:2493427.

29 McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-48. PMid:29462280.

30 Al-Abed YA, Gray EA, Rothnie ND. Outcomes of emergency colectomy for fulminant Clostridium difficile colitis. Surgeon. 2010;8(6):330-3. PMid:20950772.

31 Freedberg DE, Salmasian H, Cohen B, Abrams JA, Larson EL. Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed. JAMA Intern Med. 2016;176(12):1801-8. PMid:27723860.

32 Dubberke ER. Preventing Clostridium difficile infection: clarifying common misperceptions [Internet]. Medscape; 2015 [cited 2023 July 10]. Available from:

33 Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(05):431-55. PMid:20307191.

34 McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320(4):204-10. PMid:2911306.

35 Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994;18(2):181-7. PMid:8161624.

36 Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029-44. PMid:34164674.

37 Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol. 2009;15(13):1554-80. PMid:19340897.

38 McFarland LV. Update on the changing epidemiology of clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2008;5(1):40-8. PMid:18174906.

39 Guh AY, Kutty PK. Clostridioides difficile Infection. Ann Intern Med. 2018;169(7):ITC49-64. PMid:30285209.

40 Al Momani LA, Abughanimeh O, Boonpherg B, Gabriel JG, Young M. Fidaxomicin vs vancomycin for the treatment of a first episode of Clostridium difficile infection: A meta-analysis and systematic review. Cureus. 2018;10(6):e2778. PMid:30112254.

41 Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med. 2011;364(5):422-31. PMid:21288078.

42 Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-9. PMid:22321770.

43 Dutta SK, Girotra M, Garg S, et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2014;12(9):1572-6. PMid:24440222.

44 Hecker MT, Obrenovich ME, Cadnum JL, et al. Fecal microbiota transplantation by freeze-dried oral capsules for recurrent Clostridium difficile infection. Open Forum Infect Dis. 2016;3(2):ofw091. PMid:27822485.

45 Fischer M, Sipe B, Cheng Y-W, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8(3):289-302. PMid:28001467.

46 Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442-9. PMid:16322602.

47 Barth H, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus Proteins. Microbiol Mol Biol Rev. 2004;68(3):373-402. PMid:15353562.

48 Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539-48. PMid:25875259.

49 McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene–variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433-41. PMid:16322603.

50 Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079-84. PMid:16182895.

51 Farooq PD, Urrunaga NH, Tang DM, von Rosenvinge EC. Pseudomembranous colitis. Dis Mon. 2015;61(5):181-206. PMid:25769243.

52 Salen P, Stankewicz HA. Pseudomembranous Colitis [Internet]. StatPearls; 2023 [cited 2023 July 10]. Available from:

53 Said Fadi Yassin M. Pseudomembranous colitis surgery [Internet]. Medscape; 2023 [cited 2023 July 10]. Available from:

54 Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect. 2001;7(8):421-7. PMid:11591205.

55 Samore MH, Venkataraman L, DeGirolami PC, Arbeit RD, Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med. 1996;100(1):32-40. PMid:8579084.

56 Baktash A, Terveer EM, Zwittink RD, et al. Mechanistic insights in the success of fecal microbiota transplants for the treatment of Clostridium difficile infections. Front Microbiol. 2018;9:1242. PMid:29946308.

57 Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2(1):16020. PMid:27158839.

58 Landelle C, Verachten M, Legrand P, Girou E, Barbut F, Buisson CB. Contamination of healthcare workers’ hands with Clostridium difficile spores after caring for patients with C. difficile infection. Infect Control Hosp Epidemiol. 2014;35(1):10-5. PMid:24334792.

59 Guerrero DM, Nerandzic MM, Jury LA, Jinno S, Chang S, Donskey CJ. Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium difficile infection and with environmental surfaces in their rooms. Am J Infect Control. 2012;40(6):556-8. PMid:21982209.

60 Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee. Society for Healthcare Epidemiology of America. Association for Professionals in Infection Control. Infectious Diseases Society of America. Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol. 2002;23(12, Suppl):S3-40. PMid:12515399.

61 Turner NA, Anderson DJ. Hospital infection control: Clostridioides difficile. Clin Colon Rectal Surg. 2020;33(2):98-108. PMID: 32104163.

62 Stone SP, Fuller C, Savage J, et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. BMJ. 2012;344:e3005. PMid:22556101.

63 Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2015;64(35):988-988. PMid:26355734.

64 Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol. 2021;14:17562848211018654. PMid:34104214.

Submitted date:

Accepted date:

Publication date:

65566a15a95395471b7ed9c2 autopsy Articles
Links & Downloads

Autops Case Rep

Share this page
Page Sections